Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists.
Leptin put peptides on the obesity research map. Back in the ‘90s, researchers thought they’d found the master switch for body weight control. Fast forward: Leptin resistance threw a wrench in that theory. But the field didn’t stall. Now, glucagon-like peptide-1 (GLP-1) receptor agonists are driving a new era for metabolic research.
J Appl Genet
by Idowu TO, Chmurzynska A
“Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists. Idowu TO(1), Chmurzynska A(2). Author information: (1)Department of Human Nutrition and Dietetics, Poznań University of Life Sciences, Wojska Polskiego 31, Poznań, 60- 624, Poland. (2)Department of Human Nutrition and Dietetics, Poznań University of Life Sciences, Wojska Polskiego 31, Poznań, 60- 624, Poland. agata.chmurzynska@up.poznan.pl. The global obesity epidemic involves a multifaceted interplay between genetics, environment, and the interactions between them. The discovery of leptin in 1994 changed our understanding of body weight regulation and triggered extensive genetic studies into monogenic and polygenic obesity. Despite initial therapeutic hopes, leptin's efficacy in obesity was limited by leptin resistance. However, glucagon-like peptide-1, an incretin hormone, has become an important tool for managing obesity. Glucagon-like peptide-1 receptor agonists aid in weight loss and glycemic control while also providing metabolic and cardiovascular benefits. This article presents the shift from leptin biology to the therapeutic application of glucagon-like peptide-1 receptor analogs, focusing on their unique mechanisms, gene polymorphisms, and the hormonal interactions that regulate energy homeostasis. It outlines the shift from leptin-based theories to therapies focused on glucagon-like peptide-1 as we have gained understanding of the gut-brain-adipose axis, paving the way for targeted therapies in obesity management. © 2026. The Author(s). Conflict of interest statement: Declarations. Conflict of interest: The authors declare no conflict of interest.”
GLP-1 isn’t just any peptide. It’s an incretin hormone—triggered by food, it helps manage blood sugar and appetite. GLP-1 receptor agonists mimic this effect and do more than just help with weight loss. Studies show they can improve glycemic control and support cardiovascular health. That’s a big leap from where leptin left off.
Here’s what makes GLP-1 research stand out:
Unique mechanism: GLP-1 targets the gut-brain-adipose axis, not just a single pathway.
Genetic angle: Researchers now dig into gene polymorphisms to understand who might benefit most.
Broader effects: The metabolic and cardiovascular perks are hard to ignore.
The takeaway: We’re not stuck with the old one-hormone-fits-all model. The shift from leptin to GLP-1 approaches shows how peptide science keeps evolving. Each discovery opens new angles for targeted research—whether it’s the molecular genetics of obesity or the hormonal crosstalk that regulates energy.
If you want the full picture of how peptides are shaping obesity science, check out the peptide research index. This is where the next breakthroughs are brewing. Peptides aren’t just a passing trend—they’re changing how researchers think about weight, metabolism, and health.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.